Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Ninlaro | Ixazomib | Multiple Myeloma | Do not reimburse | Complete | ||
| Alecensaro | Alectinib | Non-Small Cell Lung Cancer | Do not reimburse | Complete | ||
| Rituxan | Rituximab | Acute Lymphoblastic Leukemia | Do not reimburse | Complete | ||
| Zaltrap | Aflibercept | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
| Zydelig | Idelalisib | Follicular Lymphoma | Do not reimburse | Complete | ||
| Egrifta | Tesamorelin | Lipodystrophy, HIV-infected patients | Do not reimburse | Complete | ||
| Darzalex | Daratumumab | Multiple Myeloma | Do not reimburse | Complete | ||
| Imbruvica | Ibrutinib | Waldenstrom's Macroglobulinemia | Do not reimburse | Complete | ||
| Fentora | Fentanyl buccal | Pain (breakthrough), cancer (adults) | Do not reimburse | Complete | ||
| Cortiment | Budesonide | Ulcerative Colitis | Do not reimburse | Complete |
Last Updated : May 13, 2024